NCT01196455

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (estimated)
• Sponsor: Croatian Cooperative Group for Clinical Research in Oncology · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.

Conditions

• Breast Cancer
• Metastasis

Interventions

Type	Name	Description
DRUG	Capecitabine and Mitomycin C	* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks * Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks

Timeline

• Start date: 2006-03-01
• Primary completion: 2011-04-01
• First posted: 2010-09-08
• Last updated: 2010-09-08

Locations

1 site across 1 country: Croatia